Back to Agenda
COVID-19 Real-World Data Analysis and Vaccine Surveillance: Examples from FDA and The Danish Medicines Agency’s Approaches
Session Chair(s)
Jesper Kjær, MS
Director for Public, Private Partnerships - Science, Policy & Intelligence, Novo Nordisk A/S, Denmark
This session will include presentations of the Danish Medicines Agency's COVID-19 cohort data analyses, the FDA’s N3C Data Enclave and the vaccine surveillance on COVID-19 patients using real-world data (RWD) from registries as examples of regulatory use of RWD during the COVID-19 pandemic.
Learning Objective : Describe the novel use of real-world data (RWD) during the COVID-19 pandemic; Describe, discuss, and evaluate the different opportunities and challenges in use of RWD given different healthcare settings and access to healthcare data.
Speaker(s)
DAC COVID: Exemplified by the Most Recent Analysis on Post-Acute Effects of Covid 19
Stine Hasling Mogensen, MPharm
Senior Scientific Advisor, Danish Medicines Agency, Denmark
Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination in Denmark and Norway: Population-Based Cohort Study
Anton Pottegaard, DRSc, PhD, MPharm
Head of Research at the Hospital Pharmacy; Professor, University of Southern Denmark, Denmark
Off-Label Use Monitoring Through Danish Registries
Mona Vestergaard Laursen, MPharm
Senior Advisor, Data Analytics Centre, Danish Medicines Agency, Denmark
FDA Real-World Evidence Activities Related to Covid19
Mitra Rocca, MSc
Associate Director, Medical Informatics, Office of Translational Science, CDER, FDA, United States
COVID-19 Real-World Data Analysis and Vaccine Surveillance: Examples from FDA and Their Novel Approach to Rapid Safety Surveillance
Richard Forshee, PhD
Associate Director of Benefit Risk Assessment, OSE, CDER, FDA, United States
Have an account?